Compare TITN & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TITN | PRTA |
|---|---|---|
| Founded | 1980 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Other Specialty Stores | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 443.9M | 449.7M |
| IPO Year | 2007 | 2013 |
| Metric | TITN | PRTA |
|---|---|---|
| Price | $18.39 | $9.12 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $19.00 | $19.00 |
| AVG Volume (30 Days) | 153.8K | ★ 539.6K |
| Earning Date | 05-21-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.26 |
| Revenue | ★ $2,427,107,000.00 | $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | $3.75 | N/A |
| P/E Ratio | ★ N/A | $35.04 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $13.21 | $7.58 |
| 52 Week High | $25.00 | $11.80 |
| Indicator | TITN | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.58 | 57.27 |
| Support Level | $17.24 | $8.91 |
| Resistance Level | $20.46 | $9.13 |
| Average True Range (ATR) | 0.86 | 0.41 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 45.22 | 94.87 |
Titan Machinery Inc owns and operates a network of full-service agricultural and construction equipment stores. The company sells and repairs agricultural equipment, including machinery and attachments for large-scale farming and home and gardening purposes, as well as construction equipment. It operates through following segments: The Agriculture segment sells, services, and rents machinery and related parts and attachments, for uses ranging from large-scale farming to home and garden use, The construction segment sells, services, and rents machinery, and related parts and attachments, for uses ranging from heavy construction to light industrial machinery use, and the Europe and Australia segments.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.